Skip to main content
Top
Published in: Journal of Neuro-Oncology 1/2017

01-10-2017 | Clinical Study

Definitive chemoradiation at high volume facilities is associated with improved survival in glioblastoma

Authors: Waqar Haque, Vivek Verma, E. Brian Butler, Bin S. Teh

Published in: Journal of Neuro-Oncology | Issue 1/2017

Login to get access

Abstract

The standard of care for glioblastoma (GBM) is maximal safe resection followed by concurrent chemoradiation (CRT). For several neoplasms, receipt of radiation treatment at high-volume facilities has been associated with improved overall survival (OS). The purpose of the present investigation was to determine if there was an association between receipt of CRT for GBM at facilities with a higher case volume and improved OS. The National Cancer Data Base was queried for patients with GBM diagnosed between 2006 and 2012 that received full-course CRT. Statistics included Kaplan–Meier analysis to compare OS between patients treated facilities with the highest quartile volume (HVF) to those treated at lower case volume facilities, multivariate logistic regression to determine factors associated with treatment at a HVF, and Cox proportional hazards modeling to determine variables associated with OS. A total of 4892 patients met the specified criteria. Fourteen facilities (9.9%) treated the highest quartile volume of patients, while 69 (48.6%) treated the lowest quartile volume (LVF) of patients. Treatment at the HVF was associated with improved median OS (16.5 vs. 14.1 months, p < 0.001). Treatment at a LVF also independently predicted for worse OS on multivariate analysis, along with age >70 years, and a resection limited to a biopsy. This is the first study to demonstrate that treatment of GBM with CRT at a HVF is associated with improved survival. Major goals of future oncologic care should be to achieve greater standardization of quality of treatment across facilities with different case volumes.
Literature
2.
go back to reference Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996CrossRefPubMed Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996CrossRefPubMed
4.
go back to reference Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randmoised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466CrossRefPubMed Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randmoised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466CrossRefPubMed
5.
go back to reference Gilbert MR, Wang M, Aldape KD et al (2013) Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 32:4085–4091CrossRef Gilbert MR, Wang M, Aldape KD et al (2013) Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 32:4085–4091CrossRef
6.
go back to reference Gilbert MR, Dignam JJ, Armstrong TS et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. New Engl. J Med 370:699–708 Gilbert MR, Dignam JJ, Armstrong TS et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. New Engl. J Med 370:699–708
7.
go back to reference Chinot OL, Wick W, Henriksoon R et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–722CrossRefPubMed Chinot OL, Wick W, Henriksoon R et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–722CrossRefPubMed
8.
go back to reference Stupp R, Taillibert S, Kanner AA et al (2015) Maintenance therapy with tumor-treaing fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA 314:2535–2543CrossRefPubMed Stupp R, Taillibert S, Kanner AA et al (2015) Maintenance therapy with tumor-treaing fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA 314:2535–2543CrossRefPubMed
9.
go back to reference Bernard-Arnoux F, Lamure M, Ducray F et al (2016) The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma. Neuro Oncol 18:1129–1136CrossRefPubMedPubMedCentral Bernard-Arnoux F, Lamure M, Ducray F et al (2016) The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma. Neuro Oncol 18:1129–1136CrossRefPubMedPubMedCentral
10.
go back to reference Liu CJ, Chou YJ, Teng CJ et al (2015) Association of surgeon volume and hospital volume with the outcome of patients receiving definitive surgery for colorectal cancer: a nationwide population-based study. Cancer 121:2782–2790CrossRefPubMed Liu CJ, Chou YJ, Teng CJ et al (2015) Association of surgeon volume and hospital volume with the outcome of patients receiving definitive surgery for colorectal cancer: a nationwide population-based study. Cancer 121:2782–2790CrossRefPubMed
11.
go back to reference Tuggle CT, Patel A, Broer N et al (2014) Increased hospital volume is associated with improved outcomes following abdominal-based breast reconstruction. J Plast Surg Hand Surg 48:382–388CrossRefPubMed Tuggle CT, Patel A, Broer N et al (2014) Increased hospital volume is associated with improved outcomes following abdominal-based breast reconstruction. J Plast Surg Hand Surg 48:382–388CrossRefPubMed
12.
go back to reference Gratian L, Pura J, Dinan M et al (2014) Treatment patterns and outcomes for patients with adrenocortical carcinoma associated with hospital case volume in the United States. Ann Surg Oncol 21:3509–3514CrossRefPubMedPubMedCentral Gratian L, Pura J, Dinan M et al (2014) Treatment patterns and outcomes for patients with adrenocortical carcinoma associated with hospital case volume in the United States. Ann Surg Oncol 21:3509–3514CrossRefPubMedPubMedCentral
13.
go back to reference Wang EH, Rutter CE, Corso CD et al (2015) Patients selected for definitive concurrent chemoradiation at high-volume facilities achieve improved survival in stage III non-small-cell lung cancer. J Thorac Oncol 10:937–943CrossRefPubMed Wang EH, Rutter CE, Corso CD et al (2015) Patients selected for definitive concurrent chemoradiation at high-volume facilities achieve improved survival in stage III non-small-cell lung cancer. J Thorac Oncol 10:937–943CrossRefPubMed
14.
go back to reference Amini A, Jones BL, Ghosh D et al (2017) Impact of facility volume on outcomes in patients with squamous cell carcinoma of the anal canal: analysis of the National Cancer Data Base. Cancer 123:228–236CrossRefPubMed Amini A, Jones BL, Ghosh D et al (2017) Impact of facility volume on outcomes in patients with squamous cell carcinoma of the anal canal: analysis of the National Cancer Data Base. Cancer 123:228–236CrossRefPubMed
15.
go back to reference Chen YW, Mahal BA, Muralidhar V et al (2016) Association between treatment at a high-volume facility and improved survival for radiation-treated men with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 15:683–690CrossRef Chen YW, Mahal BA, Muralidhar V et al (2016) Association between treatment at a high-volume facility and improved survival for radiation-treated men with high-risk prostate cancer. Int J Radiat Oncol Biol Phys 15:683–690CrossRef
16.
go back to reference Kann BH, Park HS, Lester-Coll NH et al (2016) Postoperative radiotherapy patterns of care and survival implications for medulloblastoma in young children. JAMA Oncol 2:1574–1581CrossRefPubMed Kann BH, Park HS, Lester-Coll NH et al (2016) Postoperative radiotherapy patterns of care and survival implications for medulloblastoma in young children. JAMA Oncol 2:1574–1581CrossRefPubMed
17.
go back to reference Lin JF, Berger JL, Krivak TC et al (2014) Impact of facility volume on therapy and survival for locally advanced cervical cancer. Gynecol Oncol 132:416–422CrossRefPubMed Lin JF, Berger JL, Krivak TC et al (2014) Impact of facility volume on therapy and survival for locally advanced cervical cancer. Gynecol Oncol 132:416–422CrossRefPubMed
18.
go back to reference Chen AY, Fedewa S, Pavluch A et al (2010) Improved survival is associated with treatment at high-volume teaching facilities for patients with advanced stage laryngeal cancer. Cancer 116:4744–4752CrossRefPubMed Chen AY, Fedewa S, Pavluch A et al (2010) Improved survival is associated with treatment at high-volume teaching facilities for patients with advanced stage laryngeal cancer. Cancer 116:4744–4752CrossRefPubMed
19.
go back to reference Bilimoria K, Stewart A, Winchester D, Ko C (2008) The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol 15:683–690CrossRefPubMedPubMedCentral Bilimoria K, Stewart A, Winchester D, Ko C (2008) The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol 15:683–690CrossRefPubMedPubMedCentral
20.
go back to reference Haque W, Verma V, Butler EB, Teh BS (2017) Patterns of care and outcomes of multi-agent versus single-agent chemotherapy as part of multimodal management of low grade glioma. J Neurooncol. doi:10.1007/s11060-017-2443-7 Haque W, Verma V, Butler EB, Teh BS (2017) Patterns of care and outcomes of multi-agent versus single-agent chemotherapy as part of multimodal management of low grade glioma. J Neurooncol. doi:10.​1007/​s11060-017-2443-7
21.
go back to reference Haque W, Verma V, Fakhreddine M et al (2017) Addition of chemotherapy to definitive radiotherapy for IB1 and IIA1 cervical cancer: analysis of he National Cancer Data Base. Gynecol Oncol 144:28–33CrossRefPubMed Haque W, Verma V, Fakhreddine M et al (2017) Addition of chemotherapy to definitive radiotherapy for IB1 and IIA1 cervical cancer: analysis of he National Cancer Data Base. Gynecol Oncol 144:28–33CrossRefPubMed
22.
go back to reference Moreno AC, Verma V, Hofstetter WL, Lin SH (2017) Patterns of care and treatment outcomes of elderly patients with stage I esophageal cancer: analysis of the National Cancer Data Base. J Thorac Oncol 12:1152–1160CrossRefPubMed Moreno AC, Verma V, Hofstetter WL, Lin SH (2017) Patterns of care and treatment outcomes of elderly patients with stage I esophageal cancer: analysis of the National Cancer Data Base. J Thorac Oncol 12:1152–1160CrossRefPubMed
23.
go back to reference Aneja S, Smith BD, Gross CP et al (2012) Geographic analysis of the radiation oncology workforce. Int J Radiat Oncol Biol Phys 82:1723–1729CrossRefPubMed Aneja S, Smith BD, Gross CP et al (2012) Geographic analysis of the radiation oncology workforce. Int J Radiat Oncol Biol Phys 82:1723–1729CrossRefPubMed
24.
go back to reference Thumma SR, Fairbanks RK, Lamoreaux WT et al (2012) Effect of pretreatment clinical factors on overall survival in glioblastoma multiforme: a Surveillance Epidemiology and End Results (SEER) population analysis. World J Surg Oncol 10:75CrossRefPubMedPubMedCentral Thumma SR, Fairbanks RK, Lamoreaux WT et al (2012) Effect of pretreatment clinical factors on overall survival in glioblastoma multiforme: a Surveillance Epidemiology and End Results (SEER) population analysis. World J Surg Oncol 10:75CrossRefPubMedPubMedCentral
25.
go back to reference Barnholtz-Sloan JS, Maldonado JL, Williams VL et al (2007) Racial/ethnic differences in survival among older patients with a primary glioblastoma. J Neurooncol 85:171–180CrossRefPubMed Barnholtz-Sloan JS, Maldonado JL, Williams VL et al (2007) Racial/ethnic differences in survival among older patients with a primary glioblastoma. J Neurooncol 85:171–180CrossRefPubMed
26.
go back to reference Das A, Tan WL, Teo J, Smith DR (2002) Glioblatoma multiforme in an Asian population: evidence for a distinct genetic pathway. J Neuroncol 60:117–125CrossRef Das A, Tan WL, Teo J, Smith DR (2002) Glioblatoma multiforme in an Asian population: evidence for a distinct genetic pathway. J Neuroncol 60:117–125CrossRef
Metadata
Title
Definitive chemoradiation at high volume facilities is associated with improved survival in glioblastoma
Authors
Waqar Haque
Vivek Verma
E. Brian Butler
Bin S. Teh
Publication date
01-10-2017
Publisher
Springer US
Published in
Journal of Neuro-Oncology / Issue 1/2017
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-017-2563-0

Other articles of this Issue 1/2017

Journal of Neuro-Oncology 1/2017 Go to the issue